• DOI:10.1016/S1473-3099(20)30843-4
Corpus ID: 227099817

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

@article{Zhang2020SafetyTA,
  title={Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial},
  author={Y. Zhang and G. Zeng and H. Pan and Changgui Li and Ya-ling Hu and Kai Chu and W. Han and Zhen Chen and Rong Tang and Weidong Yin and X. Chen and Yuansheng Hu and X. Liu and Congbing Jiang and J. Li and Minnan Yang and Y. Song and X. Wang and Qiang Gao and F. Zhu},
  journal={The Lancet. Infectious Diseases},
  year={2020},
  volume={21},
  pages={181 - 192}
}

Y. Zhang, G. Zeng, +17 authors F. Zhu

Published 2020

Medicine

The Lancet. Infectious Diseases

Background With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability and immunogenicity. Methods In this randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, healthy… CONTINUE READING

View on Elsevier

thelancet.com

Save to Library

Create Alert

Cite

Launch Research Feed